Xie Cheng-long, Wang Wen-Wen, Zhang Su-Fang, Gan Jing, Liu Zhen-Guo
Department of Neurology, Xinhua Hospital affiliated to the Medical School of Shanghai Jiaotong University, 200092, 1665 Kongjiang Road, Shanghai, China.
The center of Traditional Chinese Medicine, the second affiliated hospital of Wenzhou Medical University, Wenzhou 325027, China.
Sci Rep. 2014 Aug 12;4:6027. doi: 10.1038/srep06027.
A systematic review of the literature was conducted to identify randomized trials involving continuous dopaminergic stimulation (CDS) in PD patients with motor complications. Difference between n groups was assessed by partitioning heterogeneity and using the χ2 distribution with n-1 degrees of freedom, where n equals the number of groups. We looked for publication bias using funnel plotting, Egger's test and Begg's test. Twenty Randomized Controlled Trials (RCTs) were included. The results showed that CDS could evidently improve the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (p < 0.0001), part III (P < 0.00001) and UPDRS total score (p < 0.00001). There was also a statistical discrepancy in off time reduction (p < 0.00001) and prolongation of on time (p < 0.00001) by the CDS therapy compared with control groups. Meanwhile, the results of this study showed obvious side effects in the CDS therapy compared with the placebo, especially at the expense of increased dyskinesia (23.4% vs 11.7%). The present study showed that CDS was beneficial in the treatment of PD patients with motor complications. But the incidence of the side events is more common than placebo.
进行了一项文献系统综述，以确定涉及帕金森病（PD）运动并发症患者持续多巴胺能刺激（CDS）的随机试验。通过划分异质性并使用自由度为n - 1的χ2分布来评估n组之间的差异，其中n等于组数。我们使用漏斗图、Egger检验和Begg检验来寻找发表偏倚。纳入了20项随机对照试验（RCT）。结果表明，CDS可显著改善统一帕金森病评定量表（UPDRS）第二部分（p < 0.0001）、第三部分（P < 0.00001）以及UPDRS总分（p < 0.00001）。与对照组相比，CDS治疗在减少关期时间（p < 0.00001）和延长开期时间（p < 0.00001）方面也存在统计学差异。同时，本研究结果显示，与安慰剂相比，CDS治疗存在明显的副作用，尤其是以运动障碍增加为代价（23.4%对11.7%）。本研究表明，CDS对治疗PD运动并发症患者有益。但不良事件的发生率比安慰剂更常见。
